{"id":"NCT01001208","sponsor":"Amgen","briefTitle":"The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2010-12","completion":"2011-02","firstPosted":"2009-10-26","resultsPosted":"2013-08-12","lastUpdate":"2013-08-12"},"enrollment":478,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Methotrexate","otherNames":[]},{"type":"DRUG","name":"Etanercept","otherNames":["Enbrel"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Etanercept Plus Methotrexate","type":"EXPERIMENTAL"},{"label":"Etanercept Plus Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of adding methotrexate to etanercept compared with etanercept monotherapy as measured by the percentage of participants achieving a 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI 75) at Week 24.","primaryOutcome":{"measure":"PASI 75 Response at Week 24","timeFrame":"Baseline and 24 Weeks","effectByArm":[{"arm":"Etanercept + Methotrexate","deltaMin":77.3,"sd":null},{"arm":"Etanercept + Placebo","deltaMin":60.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":57},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":239},"commonTop":["Nasopharyngitis","Headache","Upper Respiratory Tract Infection","Nausea"]}}